secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-090891
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics Q2 net loss widens to $53.5M; cuts workforce 58%, cash runway to mid-2024
--------------------------------------------------------------------------------

- Net loss of $53.5M in Q2 2023 vs $37.7M in Q2 2022; revenue of $457K from IGALMI.
- Workforce reduction from ~190 to 80 employees; annualized cash burn reduced to ~$80M.
- Cash and equivalents $127.5M as of June 30; runway extended to mid-2024 without new capital.
- Requested FDA meeting to discuss TRANQUILITY II sNDA for BXCL501 in Alzheimer's agitation.
- SERENITY III Part 2 protocol amendment to evaluate 80 mcg dose for at-home use in schizophrenia/bipolar.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923090891/0001104659-23-090891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923090891/tm2323591d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-090891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer